Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylbenzyl SCHEMBL27901541 | 0.85 | PTGS2 (0.48) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL718292 | 0.83 | PTGS2 (0.45) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28716311 | 0.83 | PTGS2 (0.65) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL21271864 | 0.83 | PTGS2 (0.45) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL718810 | 0.82 | PKM (0.44) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL124501 | 0.81 | POLB (0.48) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL718901 | 0.80 | MEN1 (0.60) | PTGS2ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL5807905 | 0.80 | PTGS2 (0.65) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL718967 | 0.80 | MEN1 (0.53) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL718415 | 0.79 | PTGS2 (0.42) | PTGS2ALDH1A1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522606-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2023220223-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | claimed |
| CN-112694478-A | Nitro-substituted pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-23 | — | — | CN | claimed |
| CN-112645957-A | Pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-13 | — | — | CN | claimed |
| CN-112625044-A | Methylthio-substituted pyridazinone-structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-09 | — | — | CN | claimed |
| CN-112625045-A | 3,4, 5-trimethoxy substituted pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-09 | — | — | CN | claimed |
| CN-112608319-A | Methyl-substituted pyridazinone-structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-06 | — | — | CN | claimed |
| CN-112608323-A | Chlorine-substituted pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-06 | — | — | CN | claimed |
| CN-112608322-A | Methoxy-substituted pyridazinone-structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-06 | — | — | CN | claimed |
| CN-112608321-A | Fluorine-substituted pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | 绍兴文理学院 | 2021-04-06 | — | — | CN | claimed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| CN-112368279-B | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2024-05-28 | — | — | CN | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138876-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-20060241157-A1 | Heterocyclic ppar modulators | ELI LILLY AND COMPANY | 2006-10-26 | — | — | US | disclosed |
| EP-1585733-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885ALDH1A1 2487/4885KMT2A 1102/4885 |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MTOR, RICTOR, RPTOR | PTGS2 2866/4885ALDH1A1 4021/4885KMT2A 2637/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885ALDH1A1 2487/4885KMT2A 1102/4885 |
| US-20060241157-A1 | Heterocyclic ppar modulators | PPARA, PPARG, PPARD | PTGS2 1727/4885ALDH1A1 899/4885KMT2A 3482/4885 |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885ALDH1A1 2487/4885KMT2A 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.